Skip to main content

A Look Ahead: Precision, Safety and Access as Therapies Grow More Complex

leefam59@gmail.com
Nov 17, 2026 8:15 am

ACR Convergence 2026 closed on a high note with the Clinical Year in Preview, a forward-looking session on the final day presented by Alexis Ogdie, MD, MSCE, of the University of Pennsylvania. 

Her aim was to highlight emerging therapies, preview trials expected to report results in 2027, and define the knowledge gaps in clinical rheumatology and  the solutions needed to advance treatment and care.

To meet this challenge, Dr. Ogdie was candid that she used AI to screen the literature and narrow her sources to 163 high-priority papers published in 2026, key ACR and EULAR 2026 abstracts and 31 late-stage trials.

More Targets, More Choices

Sjögren’s disease may soon have its first targeted therapy. Ianalumab (B-cell depletion plus BAFF-R blockade) reduced disease activity in the phase 3 NEPTUNUS trials, with gains through week 108 (LB14), and is under FDA review; telitacicept was approved in China in June 2026. The trial authors called the effect small. Dr. Ogdie said, “One treatment won’t revolutionize [the] disease, but [it can change] how we think about it,” and urged better screening and education, stressing that Sjögren’s is a systemic disease.

In spondyloarthritis, options keep widening: TYK2 inhibitors, the oral IL-23 receptor antagonist icotrokinra, and sonelokimab, an IL-17A/F nanobody also positive in phase 3 hidradenitis suppurativa trials. A newer question is whether axial psoriatic arthritis (axPsA) is distinct from axial spondyloarthritis; a first definition, axial disease with imaging findings in PsA, was presented at ACR 2026. In the phase 4 STAR trial, guselkumab met its primary endpoint in MRI-confirmed axPsA. This matters because IL-23 inhibitors have failed in axial spondyloarthritis, so phenotype may decide drug choice.

Systemic lupus erythematosus (SLE) has one of the densest pipelines, with phase 3 readouts expected for litifilimab, deucravacitinib, ianalumab and cenerimod. Dr. Ogdie observed that anifrolumab challenged how lupus trials are run, and consensus on trial conduct has cleared a path for new agents. She expects a domain-based approach, as in PsA: therapy matched to the dominant manifestation (skin, joints, kidney, blood), in line with the organ-specific recommendations of the 2025 ACR SLE guideline. Lupus nephritis has long been treated this way; the shift extends that logic beyond the kidney, with more selective and oral options for a heterogeneous disease.

In gout, the URAT1 inhibitor pozdeutinurad brought serum urate below 6 mg/dL at month 6 in 69.2% (75 mg) and 56.6% (50 mg) of patients versus 8.1% with placebo in phase 3 REDUCE-2 (LB20).

Beyond Cytokine Blockade: Power With a Price

Are new pathways left to find, and can therapies be combined? Bispecific antibodies hit two pathways at once, T-cell engagers redirect T cells to deplete B cells, and cellular therapies aim to reset the immune system. Dual targeting has worked in inflammatory bowel disease, though at high cost. But greater potency brings greater risk: several autoimmune CAR-T programs were paused or stopped in 2026, including one after three participant deaths. Concerns include cytokine release syndrome, HLH, hypogammaglobulinemia, infection and unknown long-term effects.

Learning who will benefit and who may be harmed is a question for patients as much as for investigators. In ACR 2026 data on severe lupus, people valued durable benefit from CAR-T, but not apart from safety, affordability, access, fertility and their own preferences. Shared decisions begin with honest conversations about how these therapies work, what remains unknown and where they fall short, so that each person can weigh risks and benefits in light of what matters most to them.

The Immunometabolic Disease Era

Dr. Ogdie described a new era in understanding and treating rheumatic disease, using the term immunometabolic disease, driven by how clearly obesity affects disease activity and treatment response, a theme across many sessions and studies at ACR 2026. Inflamed adipose tissue and mechanical load help explain why obesity worsens gout, OA and PsA. Few rheumatologists prescribe GLP-1-based therapies today, but that may change given their potential role in supporting, rather than replacing, disease modification. One-year TOGETHER-PsA results, adding tirzepatide to ixekizumab (ACR50 44% vs 16% at 52 weeks), were a highlight of ACR 2026 and embody the concept of immunometabolic disease.

In knee OA, long without new therapy, the triple agonist retatrutide reduced WOMAC pain by 3.74 versus 2.12 points with placebo in TRIUMPH-4 and 3.64 versus 1.87 in TRIUMPH-1-OA, though the placebo response was sizable and effects on progression are unknown.

For patients losing weight, Dr. Ogdie advised monitoring blood pressure, which falls with weight loss, protecting muscle with adequate protein intake and resistance training, since sarcopenia can worsen rheumatic disease, and keeping up healthy eating and lifestyle change.

“[We] will learn more that metabolic [and] immune [factors are] relevant across rheumatic disease for inflammation and mechanical reasons,” she said.

AI: A Major Tool That Demands Critical Readers

AI is already changing research. It may reveal new disease subtypes, as immune-based profiles reclassify patients, and it may inform drug repurposing. Results depend on the data and how the model is built, and Dr. Ogdie urged caution as large AI companies such as Anthropic become life science companies. “AI cannot prioritize among what could be and should be done, and that’s where [the] expertise of having seen patients matter[s],” she said.

Dr. Ogdie sees a growing role for AI in clinical trials, which are essential to advancing therapy but resource intensive. She anticipates that AI-supported trials may allow broader eligibility, pragmatic designs, active comparators and patient-centered outcomes. ACR 2026 abstracts she highlighted that reflect these directions included lupus included a tofacitinib and glucocorticoid taper strategy in PMR (2106), a target trial emulation of avacopan in ANCA-associated vasculitis (1164), and head-to-head trials in PsA (BE BOLD, 2804) and RA (TARA, LB21). Yet recruitment remains a challenge, and it remains a human one.

Because AI makes analysis easy, the burden shifts to the reader. EHR-based studies remain prone to confounding by indication, selection bias, missing data and immortal time bias, and a fast analysis of a biased dataset is still biased. Disclosure of AI use (for example, NIH notice NOT-OD-25-132) is becoming standard. At the point of care, AI is likely to support evidence synthesis, risk prediction and disease assessment, and may push care toward consumer-driven models.

Closing the Gaps: What Rheumatology Still Needs to Learn

Dr. Ogdie closed with six knowledge gaps: why the same treatment works for some patients but not others, whether disease can be prevented, whether drug-free remission is achievable, how to treat the whole patient, how to generate evidence that reflects real-world patients, and how to turn advances into access.

For clinicians heading into 2027, the practical message is to match the drug to the patient by noting dominant domains and comorbidities such as obesity, to weigh potency against risk while being candid about what remains unknown, and to read AI-derived evidence critically, asking what data and design lie beneath it. Access matters too, because a therapy a patient cannot obtain does not help them.

The session ended on a motivating note: progress is not inevitable, and it takes better science, better trials and better care systems. With this preview, there is plenty to look forward to in the coming year and at ACR 2027 in San Francisco, CA.

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

×